Telix Pharmaceuticals Limited, A Biopharmaceutical Company Focused On The Development And Commercialisation Of Diagnostic And Therapeutic Radiopharmaceuticals, Announces That The Chinese National Medical Products Administration (Nmpa) Center For Drug Evaluation (Cde) Has Approved An Investigational New Drug (Ind) Application To Commence A Pivotal Phase Iii Registration Study Of Tlx591-Cdx (Kit For The Preparation Of 68Ga-Psma-11), For The Imaging Of Prostate Cancer Using Positron Emission Tomography (Pet) That Will Bridge To The Marketing Authorisation Granted To Illuccix By The United States Food And Drug Administration (Fda).The Ind Application Was Submitted In Partnership With Grand Pharmaceutical Group Limited (Grand Pharma), Telix
